Family: Recombinant Protein
Status: Development
Regulatory: –
Family: Reduced Folates
Status: Commercially available
Regulatory: EU • DMF
Family: Long-acting muscarinic antagonist
Status: Registration
Regulatory: US-DMF
LUGANO, March 18, 2019 • Thomas Matt, Senior Manager R&D Chemical Division at Cerbios, looks at some practical experiences in projects for ADC payloads. “During all stages of R&D activities, a process has to be developed, while also considering the containment system required and the design of the plant, so as to ensure reproducible manufacturing, of…
LUGANO, February 15, 2019 • Vitor Sousa, Senior Manager of R&D Biological Division at Cerbios, talks about the challenges that a CDMO has to solve while developing a robust and scalable process ready for cGMP production for clinical trials and later on for commercial supply. “Antibody-drug conjugates (ADCs) for oncology therapies are composed of an antibody…
LUGANO, January 18, 2019 • Cerbios-Pharma SA (from now on “Cerbios”) board of directors has approved the detailed design and budget for the installation in its High Potency Active Ingredients (HPAIs) dedicated building of a new production line able to accommodate larger volumes and batch size. Cerbios is active in the HPAI arena since 1993 with…
LUGANO, December 1st, 2018 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Dr. Francesca Scarpitta has joined our team as Director of our High Potency Active Ingredients (HPAIs) Production units. Cerbios is active in the HPAI arena since 1993, when the development of the first HPAI of category 4 (OEL<3ng/m3) started. In…
LUGANO, October 4th, 2018 • Psoriasis is a chronic disease affecting 2-4% of the world’s population. A new anti-psoriasis spray now in phase III trial offers more comfort to patients, and improves dose control. The first patient has now entered the trial. Lipidor’s Calcipotriol Spray is being evaluated over 8 weeks of treatment in a randomized…
LUGANO, October 2nd, 2018 • The Institute for Research in Biomedicine (IRB-USI, Bellinzona, www.irb.ch), active in human immunology research, and Cerbios-Pharma SA (Barbengo, Lugano), a company active in developing and producing active pharmaceutical ingredients (API), have started collaborating to develop Antibodies’ derivatives to treat Acute Myeloid Leukemia (AML), which makes it possible to target leukemia cells…
Lugano/Bern, September 7, 2018 • On September 7, Cerbios was honored by the visit of the US Ambassador to Switzerland and Liechtenstein, Edward McMullen Jr. Aim of the visit of the Ambassador was to meet Cerbios’ top management and shareholder in order to have a better view and understanding of Cerbios’ ongoing and future activities in the…
